A Review of the Aging Process and Facilities Topic

References

1. 1.↵
   1. Woodcock J.,
   2. Wosinska M.

   Economic and technological drivers of generic sterile injectable drug shortages. Clin. Pharm. Ther. 2013, 93 (2), 170–176.

   OpenUrlPubMed
2. 2.↵
   1. Bohn E.,
   2. Nogalski Krapf M.

   Master Planning Legacy Facilities: Dealing with the Issues of a “Band-Aid” Approach. International Society of Pharmaceutical Engineering ISPEAK, 2014.
3. 3.↵
   1. Miller G.

   Ben Venue inspection yields 48 GMP violations. Fierce Pharma Manufacturing Oct, 19th, 2011.
4. 4.↵
   1. Struck K.

   Quality control costs tied to drug shortages. Med Page Today Jan. 23rd, 2013.
5. 5.↵
   1. Crowe M.

   Enterprise Benefits of Quality Systems. PDA/FDA Conference, Washington, DC, Sept. 9th, 2014.
6. 6.↵
   1. Jornitz M. W.

   Flexible facilities of the future—examples. 2014 PDA Europe Conference Modern Biopharmaceutical Manufacturing, Manufacturing of the Future 25 - 26 March 2014, Lyon, France.
7. 7.↵
   1. Vinther A.

   Expediting Post Approval Regulatory Changes to Mitigate Drug Shortages. PDA Drug Shortage Workshop, Washington, DC, Sept. 8th, 2014.
8. 8.↵
   Product Quality Research Institute (PQRI). Post Approval Changes for Sterile Products Working Group, April 19th, 2007.
9. 9.↵
   International Society for Pharmaceutical Engineering (ISPE) Facility of the Year Award, Med Immune Equipment Innovation Award. ISPE, Tampa, FL, Nov. 7th, 2013.
10. 10.↵
    1. Tschumakow A.

    Single Use Systems—An End User's Perspective. IBC 2nd Annual Flexible Facilities Conference, Claremont, CA, Feb. 24th, 2014.